⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ZVRA News
Zevra Therapeutics, Inc. Common Stock
Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call
globenewswire.com
ZVRA
Zevra Therapeutics to Present at the Citizens Life Sciences Conference
globenewswire.com
ZVRA
Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer
globenewswire.com
ZVRA
Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
businesswire.com
ZVRA
Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
businesswire.com
ZVRA
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
globenewswire.com
ZVRA
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
globenewswire.com
ZVRA
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™
globenewswire.com
ZVRA
Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference
globenewswire.com
ZVRA
Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC)
globenewswire.com
ZVRA